Cancer Genetics and Epigenetics, 2025, Vol.13, No.5, 206-214 http://medscipublisher.com/index.php/cge 213 individual conditions. By using genomic and single-cell data, personalized treatment plans can be developed for different patients to adapt to the characteristics and differences of their tumors. Relying on synthetic biology technology, controllable CAR design, and interdisciplinary integration with other immunotherapies, the development of multimodal and highly adaptive treatment strategies will be promoted, ultimately making CAR-T cell therapy a conventional and effective method for treating solid tumors. Acknowledgments I would like to thank Mrs. Fang continuous support throughout the development of this study. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Ai K., Liu B., Chen X., Huang C., Yang L., Zhang W., Weng J., Du X., Wu K., and Lai P., 2024, Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies, Journal of Hematology and Oncology, 17(1): 105. https://doi.org/10.1186/s13045-024-01625-7 Albelda S., 2023, CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn, Nature Reviews Clinical, 21(1): 47-66. https://doi.org/10.1038/s41571-023-00832-4 Chen T., Wang M., Chen Y., and Liu Y., 2024, Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors, Cancer Cell International, 24(1): 133. https://doi.org/10.1186/s12935-024-03315-3 Dagar G., Gupta A., Masoodi T., Nisar S., Merhi M., Hashem S., Chauhan R., Dagar M., Mirza S., Bagga P., Kumar R., Akil A., Macha M., Haris M., Uddin S., Singh M., and Bhat A., 2023, Harnessing the potential of CAR-T cell therapy: progress challenges and future directions in hematological and solid tumor treatments, Journal of Translational Medicine, 21(1): 449. https://doi.org/10.1186/s12967-023-04292-3 Dimitri A., Herbst F., and Fraietta J., 2022, Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing, Molecular Cancer, 21(1): 78. https://doi.org/10.1186/s12943-022-01559-z Fonkoua L., Sirpilla O., Sakemura R., Siegler E., and Kenderian S., 2022, CAR T cell therapy and the tumor microenvironment: current challenges and opportunities, Molecular Therapy Oncolytics, 25: 69-77. https://doi.org/10.1016/j.omto.2022.03.009 Guzman G., Reed M., Bielamowicz K., Koss B., and Rodriguez A., 2023, CAR-T therapies in solid tumors: opportunities and challenges, Current Oncology Reports, 25: 479-489. https://doi.org/10.1007/s11912-023-01380-x Hou A., Chen L., and Chen Y., 2021, Navigating CAR-T cells through the solid-tumour microenvironment, Nature Reviews Drug Discovery, 20: 531-550. https://doi.org/10.1038/s41573-021-00189-2 Khan S., Choi Y., Veena M., Lee J., and Shin D., 2025, Advances in CAR T cell therapy: antigen selection modifications and current trials for solid tumors, Frontiers in Immunology, 15: 1489827. https://doi.org/10.3389/fimmu.2024.1489827 Knochelmann H., Smith A., Dwyer C., Wyatt M., Mehrotra S., and Paulos C., 2018, CAR T cells in solid tumors: blueprints for building effective therapies, Frontiers in Immunology, 9: 1740. https://doi.org/10.3389/fimmu.2018.01740 Larson R., Kann M., Bailey S., Haradhvala N., Llopis P., Bouffard A., Scarfò I., Leick M., Grauwet K., Berger T., Stewart K., Anekal P., Jan M., Joung J., Schmidts A., Ouspenskaia T., Law T., Regev A., Getz G., and Maus M., 2022, CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours, Nature, 604: 563-570. https://doi.org/10.1038/s41586-022-04585-5 Li M.M., 2024, Immune checkpoint blockade in renal cell carcinoma: therapeutic efficacy and mechanisms of resistance, International Journal of Clinical Case Reports, 14(4): 189-201. https://doi.org/10.5376/ijccr.2024.14.0020 Lou Q.Y., and Xu X.Y., 2025, Trends in CAR-T cell therapy for hematologic malignancies, Cancer Genetics and Epigenetics, 13(3): 136-144. https://doi.org/10.5376/cge.2025.13.0014 Ma S., Li X., Wang X., Cheng L., Li Z., Zhang C., Ye Z., and Qian Q., 2019, Current progress in CAR-T Cell therapy for solid tumors, International Journal of Biological Sciences, 15: 2548-2560. https://doi.org/10.7150/ijbs.34213 Maalej K., Merhi M., Inchakalody V., Mestiri S., Alam M., Maccalli C., Cherif H., Uddin S., Steinhoff M., Marincola F., and Dermime S., 2023, CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances, Molecular Cancer, 22(1): 20. https://doi.org/10.1186/s12943-023-01723-z
RkJQdWJsaXNoZXIy MjQ4ODYzNA==